Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Schubert Firm Investigating Possible Legal Claims on Behalf of Vaxart, Inc. Shareholders

VXRT

SAN FRANCISCO, July 27, 2020 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Vaxart, Inc. (Nasdaq: VXRT) and certain of its insiders on behalf of shareholders.

The firm's investigation relates to stock sales made by the corporation's largest shareholder in June 2020. According to an article published by the New York Times on July 25, 2020, Vaxart's largest shareholder, hedge fund Armistice Capital, has made substantial profits from the rush for the coronavirus vaccine. In the spring of 2020, Vaxart began development of an orally administered Covid-19 vaccine. During this time, Vaxart also amended the terms of its warrants agreement with Armistice Capital making it easier for the hedge fund to rapidly acquire and sell shares.

On June 26, 2020, Vaxart issued a news release announcing that it had been selected for Operation Warp Speed, the federal initiative to quickly develop drugs to combat the coronavirus. The truth was more complex. Vaxart's Covid-19 vaccine candidate was included in a trial on primates that a federal agency organized in conjunction with Operation Warp Speed. However, Vaxart is not among the companies selected to receive significant financial support from Operation Warp Speed. Following Vaxart's June 26th announcement, Armistice exercised its newly amended warrants to buy nearly 21 million Vaxart shares and immediately sold them, making an immense $197 million profit.

The Schubert Firm is investigating potential legal claims based on the reconfigured warrants agreement when company insiders may have known about Vaxart's role in Operation Warp Speed. If you wish to obtain additional information about shareholder claims and your legal rights, please contact Kathryn McCauley via email at kmccauley@sjk.law or by telephone at (415) 788-4220, or fill out the form on our website at www.classactionlawyers.com/VXRT.

About Schubert Jonckheer & Kolbe

Schubert Jonckheer & Kolbe has extensive experience in prosecuting securities claims and has successfully represented investors throughout the nation in shareholder lawsuits.

Attorney advertising. Prior results do not guarantee similar outcomes.

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-schubert-firm-investigating-possible-legal-claims-on-behalf-of-vaxart-inc-shareholders-301099948.html

SOURCE Schubert Jonckheer & Kolbe LLP



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today